Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127238001 | 12723800 | 1 | I | 20120606 | 20140304 | 20160908 | 20160908 | EXP | DE-ABBVIE-16P-062-1721765-00 | ABBVIE | 85.00 | YR | F | Y | 76.00000 | KG | 20160908 | MD | COUNTRY NOT SPECIFIED | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127238001 | 12723800 | 1 | PS | ZEMPLAR | PARICALCITOL | 1 | Intravenous (not otherwise specified) | UNKNOWN | 20819 | 15 | UG | INJECTION | /wk | ||||||
| 127238001 | 12723800 | 2 | C | RENVELA | SEVELAMER CARBONATE | 1 | Oral | 0 | 2.8 | G | /wk | ||||||||
| 127238001 | 12723800 | 3 | C | RENVELA | SEVELAMER CARBONATE | 1 | Oral | 33.6G TOTAL WEEKLY CUMULATIVE DOSE | 0 | 33.6 | G | ||||||||
| 127238001 | 12723800 | 4 | C | EPOETIN ALFA | ERYTHROPOIETIN | 1 | Intravenous (not otherwise specified) | 12000 IU TOTAL WEEKLY CUMULATIVE DOSE | 0 | /wk | |||||||||
| 127238001 | 12723800 | 5 | C | TOREM | TORSEMIDE | 1 | Oral | 1400MG CUMULATIVE WEEKLY DOSE | 0 | ||||||||||
| 127238001 | 12723800 | 6 | C | ASPIRIN. | ASPIRIN | 1 | 7 TABLETS IN ONE WEEK | 0 | TABLET | ||||||||||
| 127238001 | 12723800 | 7 | C | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Oral | 280MG TOTAL CUMULATIVE WEEKLY DOSE | 0 | ||||||||||
| 127238001 | 12723800 | 8 | C | METAMIZOL | METAMIZOLE SODIUM | 1 | Oral | 0 | 1 | DF | QOD | ||||||||
| 127238001 | 12723800 | 9 | C | DEKRISTOL | CHOLECALCIFEROL | 1 | Oral | 0 | 20000 | IU | /month | ||||||||
| 127238001 | 12723800 | 10 | C | NOVAMINSULFON | METAMIZOLE | 1 | AS REQUIRED | 0 | |||||||||||
| 127238001 | 12723800 | 11 | C | LOPERAMIDE | LOPERAMIDE | 1 | AS REQUIRED | 0 | |||||||||||
| 127238001 | 12723800 | 12 | C | NIFEDIPINE. | NIFEDIPINE | 1 | AS REQUIRED | 0 | 10 | GTT | |||||||||
| 127238001 | 12723800 | 13 | C | FERRLECIT | SODIUM FERRIC GLUCONATE COMPLEX | 1 | Intravenous (not otherwise specified) | 0 | 40 | MG | /wk |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127238001 | 12723800 | 1 | Hyperparathyroidism secondary |
| 127238001 | 12723800 | 2 | Blood phosphorus increased |
| 127238001 | 12723800 | 4 | Product used for unknown indication |
| 127238001 | 12723800 | 5 | Product used for unknown indication |
| 127238001 | 12723800 | 6 | Product used for unknown indication |
| 127238001 | 12723800 | 7 | Product used for unknown indication |
| 127238001 | 12723800 | 8 | Product used for unknown indication |
| 127238001 | 12723800 | 9 | Product used for unknown indication |
| 127238001 | 12723800 | 10 | Product used for unknown indication |
| 127238001 | 12723800 | 11 | Product used for unknown indication |
| 127238001 | 12723800 | 12 | Product used for unknown indication |
| 127238001 | 12723800 | 13 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127238001 | 12723800 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127238001 | 12723800 | Death |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |